Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib Long-term Extension in Crohn's and UC
NCT04877990Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2021
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
A Phase 2 trial of deucravacitinib in Crohn's disease, ulcerative colitis (UC), sponsored by Bristol Myers Squibb. Started May 2021; status: completed.
02
Drugs
deucravacitinib
03
Conditions
Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04877990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04877990.